Literature DB >> 20515833

Osteomimicry: how tumor cells try to deceive the bone.

Nadia Rucci1, Anna Teti.   

Abstract

Bone metastases are complications of multiple myeloma and solid tumors, including breast and prostate carcinomas. Several reports have demonstrated that the preference to metastasize to bone by tumor cells is not a casual but an addressed event, which relies on specific interactions among tumor cells, bone marrow microenvironment and bone cells. One of the features that gives tumor cells more chances to survive and proliferate into the bone tissue is osteomimicry, that is the ability to acquire a bone cell phenotype, especially osteoblast-like. As clearly demonstrated, prostate and breast cancer cells try to resemble osteoblasts by expressing bone matrix proteins, the specific marker alkaline phosphatase, and molecules regulating the osteoblast/osteoclast cross-talk. Based on this evidence it is crucial to dissect in more detail the molecular mechanisms underlying the osteomimetic properties of cancer cells and identify new therapeutic targets eventually leading to a better and prolonged life expectation for patients with bone.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20515833     DOI: 10.2741/s110

Source DB:  PubMed          Journal:  Front Biosci (Schol Ed)        ISSN: 1945-0516


  32 in total

Review 1.  Tissue-engineered models of human tumors for cancer research.

Authors:  Aranzazu Villasante; Gordana Vunjak-Novakovic
Journal:  Expert Opin Drug Discov       Date:  2015-02-07       Impact factor: 6.098

Review 2.  Metastasis Organotropism: Redefining the Congenial Soil.

Authors:  Yang Gao; Igor Bado; Hai Wang; Weijie Zhang; Jeffrey M Rosen; Xiang H-F Zhang
Journal:  Dev Cell       Date:  2019-05-06       Impact factor: 12.270

3.  Canine prostate cancer cell line (Probasco) produces osteoblastic metastases in vivo.

Authors:  Jessica K Simmons; Wessel P Dirksen; Blake E Hildreth; Carlee Dorr; Christina Williams; Rachael Thomas; Matthew Breen; Ramiro E Toribio; Thomas J Rosol
Journal:  Prostate       Date:  2014-07-07       Impact factor: 4.104

Review 4.  Metastatic tumors to the jaws and mouth.

Authors:  Abraham Hirshberg; Raanan Berger; Irit Allon; Ilana Kaplan
Journal:  Head Neck Pathol       Date:  2014-11-20

Review 5.  Harnessing the versatile role of OPG in bone oncology: counterbalancing RANKL and TRAIL signaling and beyond.

Authors:  Maria V Deligiorgi; Mihalis I Panayiotidis; John Griniatsos; Dimitrios T Trafalis
Journal:  Clin Exp Metastasis       Date:  2019-10-01       Impact factor: 5.150

Review 6.  RANK-mediated signaling network and cancer metastasis.

Authors:  Gina Chia-Yi Chu; Leland W K Chung
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

Review 7.  Unique Metabolic Adaptations Dictate Distal Organ-Specific Metastatic Colonization.

Authors:  Tanya Schild; Vivien Low; John Blenis; Ana P Gomes
Journal:  Cancer Cell       Date:  2018-03-12       Impact factor: 31.743

8.  miR-218 directs a Wnt signaling circuit to promote differentiation of osteoblasts and osteomimicry of metastatic cancer cells.

Authors:  Mohammad Q Hassan; Yukiko Maeda; Hanna Taipaleenmaki; Weibing Zhang; Mohammad Jafferji; Jonathan A R Gordon; Zhaoyong Li; Carlo M Croce; Andre J van Wijnen; Janet L Stein; Gary S Stein; Jane B Lian
Journal:  J Biol Chem       Date:  2012-10-11       Impact factor: 5.157

9.  ADAM10 releases a soluble form of the GPNMB/Osteoactivin extracellular domain with angiogenic properties.

Authors:  April A N Rose; Matthew G Annis; Zhifeng Dong; Francois Pepin; Michael Hallett; Morag Park; Peter M Siegel
Journal:  PLoS One       Date:  2010-08-10       Impact factor: 3.240

10.  Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases.

Authors:  Sandy R Larson; Xiaotun Zhang; Ruth Dumpit; Ilsa Coleman; Bryce Lakely; Martine Roudier; Celestia S Higano; Lawrence D True; Paul H Lange; Bruce Montgomery; Eva Corey; Peter S Nelson; Robert L Vessella; Colm Morrissey
Journal:  Prostate       Date:  2013-01-17       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.